Home > Search: Pantothenate kinase-associated neurodegeneration

• Search Results

Search Results Get Your Free Credit Report Right Now! Zip Code: Join our discussion forums! Providers join our directory! General Topics A-Z Conditions Treatments Medications Fitness Nutrition Anatomy Travel/Destinations Other Topics From the West From the East

Main Topic Area Pantothenate kinase-associated neurodegeneration All Topic Areas 1 - 10 of 44  more >> Pantothenate kinase-associated neurodegeneration NBIA1 Neurodegeneration with Brain Iron Accumulation Type 1 PKAN Pantothenic Acid Calcium Pantothenate Vitamin B5 Neurodegeneration with Brain Iron Accumulation Pentamidine Isethionate Injection Pentam 300 Injection Articles 1 - 1 of 1 Pantothenate kinase-associated neurodegeneration Pantothenate kinase-associated neurodegeneration (formerly called Hallervorden-Spatz syndrome) is a disorder of the nervous system. The condition is characterized by progressive difficulty with movement and speech. Affected people may also experience loss of intellectual function (dementia) and problems with vision. Researchers have described classic and atypical forms of pantothenate kinase-associated neurodegeneration. Both types involve a buildup of iron in certain parts of the brain. The... Genetics Home Reference News 1 - 5 of 82  more >> New Therapeutic Target For Alzheimer's Could Lead To Drugs Without Side Effects ScienceDaily - Wed, 28 Feb 2007 04:00 EST Stress Response Prevents Neurodegeneration MedicalNewsToday - Sun, 04 Feb 2007 07:00 EST Stress Response Prevents Neurodegeneration ScienceDaily - Mon, 05 Feb 2007 04:00 EST Rigel Announces Initiation Of Phase 1 Study Evaluating R763 In Hematological Malignancies MedicalNewsToday - Wed, 14 Feb 2007 08:00 EST Researchers Discover Master Metabolism Regulator With Profound Effect On Fat Metabolism MedicalNewsToday - Tue, 13 Feb 2007 05:00 EST Clinical Trials 1 - 5 of 307  more >> Dietary Cholesterol and Defects in Cholesterol Synthesis in Mevalonate Kinase Deficiency ClinicalTrials.gov Identifier: NCT00260299 - Recruiting Mevalonic Aciduria; Mevalonate Kinase Deficiency; Immune System Diseases; Periodic Fever Syndromes, Hereditary; Lipid Metabolism, Inborn Errors A Phase I/II Trial of an Oral mTOR Protein Kinase Inhibitor (Everolimus, RAD001) in Combination with an Oral EGFR Tyrosine Kinase Inhibitor (Erlotinib, Tarceva™) in Patients with Metastatic Breast Cancer ClinicalTrials.gov Identifier: NCT00179270 - Recruiting Metastatic breast cancer An Open-Label, Non-Comparative, Phase III Study of the Raf-Kinase Inhibitor BAY 43-9006 as a Subsequent to First-Line Therapy in Patients With Advanced Renal Cell Carcinoma ClinicalTrials.gov Identifier: NCT00492986 - Active, not recruiting Cancer; Renal Cell Cancer Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction ClinicalTrials.gov Identifier: NCT00030498 - Active, not recruiting Cancer A Rho-Kinase Inhibitor (Fasudil) in the Treatment of Raynaud's Phenomenon ClinicalTrials.gov Identifier: NCT00498615 - Recruiting Raynaud's

GoldBambooTM Your Integrative Health and Wellness Resource November 30, 2009

email this page   |    print this page   |    bookmark this page   |    feedback on this page Page Updated: January 17, 2009

Disclaimer: All material displayed on the GoldBamboo.com website is provided for educational purposes only. Consult a physician regarding the applicability of any information found on GoldBamboo.com to your symptoms or medical condition.